This activity is supported by an educational grant from AbbVie, Inc.

Keeping Pace With New HCV Treatment and Management Strategies: Steps for Success in Managed Care.

Release date: September 30, 2014
Expiration date: April 29, 2016
Estimated Time to Complete Activity: 1.0 hour
Compatible with (IE 6 and up, Firefox, Safari)

Distinguished Faculty Presenters


	Jeffrey D. Dunn, PharmD, MBA Senior Vice President VRx Pharmacy Services, LLC Click here for biography


	Paul Y. Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Division of Gastroenterology and Hepatology Indiana University School of Medicine Click here for biography

Target Audience

This activity is designed to meet the educational needs of pharmacists, physicians, and other health care professionals with an interest in the management of patients with HCV.

Statement of Need/Program Overview

With the availability and future approval of protease inhibitors (PIs) for HCV, managed care organization (MCO) decision makers must consider many factors as they develop drug management strategies and tactics: drug costs, patient management needs, adherence, comparative safety and efficacy, and appropriate utilization management controls. Appropriate management strategies are critical for MCOs focused on ensuring that HCV patients receive optimal benefit from these therapies.

Educational Objectives
After completing this activity, the participant should be better able to:

Implement strategies to manage patients with HCV within a managed care setting
Utilize recently updated AASLD, IDSA, and ACG treatment guidelines on current and emerging treatment options for HCV, including efficacy, safety, and tolerability
Identify techniques for MCOs to determine the overall cost-effectiveness of HCV therapies
Evaluate pharmacy benefit management strategies, including methods that MCOs can implement to improve overall patient outcomes for HCV patients
Provide accurate and appropriate counsel as part of the treatment team

ACCREDITATION

Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Accreditation Statement


	Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – 0809-9999-14-191-H01-P)

Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

*Name of Faculty or Presenter*	*Reported Financial Relationship*
Jeffrey D. Dunn, PharmD, MBA	Consulting Fees: AbbVie, Inc., Gilead Sciences, Inc., Janssen Pharmaceuticals, and Vertex Pharmaceuticals
Paul Y. Kwo, MD	Consulting Fees: AbbVie, Inc., Bristol-Myers Squibb, Gilead Sciences, Inc., GlaxoSmithKline, Janssen Pharmaceuticals, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, and Vertex Pharmaceuticals Fees for Non-CME/CE Services: Merck & Co., Inc. Research Grant Funding: AbbVie, Inc., Bristol-Myers Squibb, Gilead Sciences, Inc., Merck & Co., Inc., Roche, and Vertex Pharmaceuticals

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

*Name of Planner or Manager*	*Reported Financial Relationship*
Steve Casebeer, MBA	No financial interest/relationships relating to the topic of this activity.
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period September 30, 2014 through April 29, 2016, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.

Media
Internet

Type of Activity
Application

Fee Information
There is no fee for this educational activity.